公开(公告)号：US20050287204A1

公开(公告)日：2005-12-29

申请号：US10518623

申请日：2003-06-19

申请人： Robert Hageman ,  George Verlaan

发明人： Robert Hageman ,  George Verlaan

IPC分类号： A23L1/302 ,  A23L1/305 ,  A61K31/195 ,  A61K38/16 ,  A61K45/06 ,  A61K31/714 ,  A61K31/198 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/525

CPC分类号： A61K45/06 ,  A23L33/15 ,  A23L33/17 ,  A23L33/175 ,  A23L33/19 ,  A61K31/195 ,  A61K38/16 ,  A61K2300/00

摘要： There is provided a nutritional or pharmaceutical composition comprising a protein fraction containing L-serine and an energy metabolism precursor wherein the composition is free of glycine or if glycine is present within the composition, the weight ratio of L-serine: glycine after hydrolysis of the composition is of more than 2.7:1, which composition provides an effective creatine response within mammals muscle and methylation reaction capacity of organisms.

摘要翻译： 提供了包含含有L-丝氨酸的蛋白质级分和能量代谢前体的营养或药物组合物，其中所述组合物不含甘氨酸，或者如果甘氨酸存在于组合物内，L-丝氨酸：甘氨酸在水解后的重量比为 组成超过2.7:1，该组合物在哺乳动物肌肉中提供有效的肌酸反应和生物体的甲基化反应能力。

公开(公告)号：US20070202194A1

公开(公告)日：2007-08-30

申请号：US11741547

申请日：2007-04-27

申请人： Amanda Kiliaan ,  Robert Hageman

发明人： Amanda Kiliaan ,  Robert Hageman

IPC分类号： A61K33/34 ,  A61K31/495 ,  A61K31/535 ,  A61K33/30

CPC分类号： A61K31/685 ,  A23L33/105 ,  A23L33/115 ,  A23L33/15 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/14 ,  A61K31/194 ,  A61K31/20 ,  A61K31/202 ,  A61K31/205 ,  A61K31/355 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/683 ,  A61K33/30 ,  A61K33/34 ,  A61K36/16 ,  A61K45/06 ,  A61K2300/00 ,  A23V2250/1842 ,  A23V2250/7052 ,  A23V2250/706 ,  A23V2250/161 ,  A23V2250/1642 ,  A23V2250/032 ,  A23V2250/1846 ,  A23V2250/1852 ,  A23V2250/1848 ,  A23V2250/156 ,  A23V2250/5114 ,  A23V2250/704 ,  A23V2250/716

摘要： The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.

摘要翻译： 本发明涉及适用于预防和/或治疗血管疾病的制剂，其包含以下级分：级分a）由长链多不饱和脂肪酸组成; 组分b）由磷脂组成，该级分含有至少两种选自磷脂酰丝氨酸，磷脂酰肌醇，磷脂酰胆碱和磷脂酰乙醇胺的不同磷脂。 组分c）由作为甲硫氨酸代谢因子的化合物组成，该级分含有选自叶酸，维生素B12，维生素B6，镁和锌中的至少一种。

公开(公告)号：US07174791B2

公开(公告)日：2007-02-13

申请号：US11176167

申请日：2005-07-07

申请人： Mark Peter Modera ,  Robert Hageman ,  Brian Farmer

发明人： Mark Peter Modera ,  Robert Hageman ,  Brian Farmer

IPC分类号： G01F1/00

CPC分类号： G01F1/10 ,  G01F1/363

摘要： A fan powered by a controlled external energy source and a flow measurement device measure the airflow exiting or entering grilles/registers of an HVAC system without impeding the airflow being measured. A flow straightening element is preferably employed to overcome any effects of a non-uniform or swirled airflow profile on the fan. Preferably, the RPM of the fan is measured to determine the airflow. The RPM/flow calibration of the fan is insensitive to pressure differentials or the fan is a pressure-sensitive fan submitted to appropriate pressure differentials. Alternatively, the voltage or current supplied to the external energy source is used to determine the airflow. Finally, the pressure differential across the flow straightening element can be measured to determine airflow, eliminating the impact of pressure differential across the flow measurement device and fan.

摘要翻译： 由受控的外部能源供电的风扇和流量测量装置测量出流或进入HVAC系统的格栅/寄存器的气流，而不会阻碍被测量的气流。 优选地采用流动矫正元件来克服风扇上的不均匀或涡流气流分布的任何影响。 优选地，测量风扇的RPM以确定气流。 风扇的RPM /流量校准对压差不敏感，或风扇是经过适当压差的压敏风扇。 或者，使用提供给外部能量源的电压或电流来确定气流。 最后，可以测量整流元件上的压力差，以确定气流，消除流量测量装置和风扇两端的压差的影响。

公开(公告)号：US20050261958A1

公开(公告)日：2005-11-24

申请号：US10848555

申请日：2004-05-18

申请人： Robert Hageman

发明人： Robert Hageman

IPC分类号： G09F25/00 ,  G06F17/60

CPC分类号： G09F25/00 ,  G06Q30/0251 ,  G06Q30/0268

摘要： The invention is of a novel business method for presenting pre-recorded promotional presentations to retail consumers at the point of sale. The system plays a short consumer message upon activation by the consumer and educates the consumer about some aspect of the product for sale. This novel business method is a way for marketers to make individualized contact with the consumer at the point of sale without the use of sales personnel.

摘要翻译： 本发明是一种新颖的业务方法，用于在销售点向零售消费者呈现预先录制的促销演示文稿。 该系统在消费者激活时发出短消息消息，并教育消费者关于该产品出售的一些方面。 这种新颖的商业方法是营销人员在不使用销售人员的情况下在销售点与消费者进行个性化联系的一种方式。

公开(公告)号：US5453490A

公开(公告)日：1995-09-26

申请号：US298180

申请日：1994-08-30

申请人： Robert Hageman ,  Stephen P. Eisenberg ,  David Dripps ,  Ronald Evans ,  Henryk Cudny ,  Robert C. Thompson

发明人： Robert Hageman ,  Stephen P. Eisenberg ,  David Dripps ,  Ronald Evans ,  Henryk Cudny ,  Robert C. Thompson

IPC分类号： C07K1/18 ,  C07K14/54 ,  C12N1/21 ,  C12N15/09 ,  C12P21/02 ,  C12R1/19 ,  C07K14/435 ,  C07K1/36

CPC分类号： C07K14/54

摘要： A method for the production of commercial quantities of highly purified interleukin-1 inhibitor (IL-1i) from a recombinant host is disclosed. A preferred recombinant E. coli host for use in this method is also disclosed.

摘要翻译： 公开了从重组宿主生产商业数量的高纯度白细胞介素-1抑制剂（IL-1i）的方法。 还公开了用于该方法的优选重组大肠杆菌宿主。

公开(公告)号：US20080020062A1

公开(公告)日：2008-01-24

申请号：US11861323

申请日：2007-09-26

申请人： Maria Verheul-Koot ,  Chantal Kleijer ,  Robert Hageman ,  Roelof Bork ,  Maud Goethals

发明人： Maria Verheul-Koot ,  Chantal Kleijer ,  Robert Hageman ,  Roelof Bork ,  Maud Goethals

IPC分类号： A61K31/045 ,  A61K31/355 ,  A61K31/375 ,  A61K33/30 ,  A61K38/02

CPC分类号： A61K33/30 ,  A23L33/105 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23L33/175 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/01 ,  A61K31/045 ,  A61K31/355 ,  A61K31/375 ,  A61K38/02 ,  A61K45/06 ,  Y10S514/905 ,  A23V2250/708 ,  A23V2250/712 ,  A23V2250/702 ,  A23V2250/704 ,  A23V2250/71 ,  A23V2250/705 ,  A23V2250/70 ,  A23V2250/1614 ,  A23V2250/1582 ,  A23V2250/16 ,  A23V2250/1578 ,  A23V2250/1618 ,  A23V2250/161 ,  A23V2250/1598 ,  A23V2250/156 ,  A23V2250/0606 ,  A23V2250/0632 ,  A23V2250/06 ,  A23V2250/2116 ,  A23V2250/0612 ,  A23V2250/0644 ,  A23V2250/304 ,  A23V2250/211 ,  A61K2300/00

摘要： The invention pertains to a method of treating or preventing pressure ulcers, comprising enterally administering to a subject in need thereof a composition comprising proteins, carbohydrates, fats, arginine or equivalents thereof, ascorbic acid equivalents and a-tocopherol equivalents, wherein arginine or equivalents thereof is administered in a daily amount of 3-15 g, ascorbic acid equivalents are administered in a daily amount of 180-840 mg and a-tocopherol equivalents are administered in a daily amount of 50-400 mg.

摘要翻译： 本发明涉及治疗或预防压力性溃疡的方法，其包括向有需要的受试者肠内施用包含蛋白质，碳水化合物，脂肪，精氨酸或其等同物，抗坏血酸当量和α-生育酚当量的组合物，其中精氨酸或其等同物 以每日3-15g的量施用抗坏血酸当量，以每日180-840mg的量施用，α-生育酚当量以每日50-400mg的量施用。

公开(公告)号：US20050241293A1

公开(公告)日：2005-11-03

申请号：US11176167

申请日：2005-07-07

申请人： Mark Modera ,  Robert Hageman ,  Brian Farmer

发明人： Mark Modera ,  Robert Hageman ,  Brian Farmer

IPC分类号： G01F1/10 ,  G01F1/36 ,  F02K3/02

CPC分类号： G01F1/10 ,  G01F1/363

摘要： A fan powered by a controlled external energy source and a flow measurement device measure the airflow exiting or entering grilles/registers of an HVAC system without impeding the airflow being measured. A flow straightening element is preferably employed to overcome any effects of a non-uniform or swirled airflow profile on the fan. Preferably, the RPM of the fan is measured to determine the airflow. The RPM/flow calibration of the fan is insensitive to pressure differentials or the fan is a pressure-sensitive fan submitted to appropriate pressure differentials. Alternatively, the voltage or current supplied to the external energy source is used to determine the airflow. Finally, the pressure differential across the flow straightening element can be measured to determine airflow, eliminating the impact of pressure differential across the flow measurement device and fan.

公开(公告)号：US20050090457A1

公开(公告)日：2005-04-28

申请号：US10504713

申请日：2003-02-14

申请人： Inez Schoenmakers ,  Zhi Chao Dang ,  Clemens Waitherus Lowik ,  Adrianus Lambertus Van Helvoort ,  Robert Hageman ,  Marijan Gros-Van

发明人： Inez Schoenmakers ,  Zhi Chao Dang ,  Clemens Waitherus Lowik ,  Adrianus Lambertus Van Helvoort ,  Robert Hageman ,  Marijan Gros-Van

IPC分类号： A61K31/352 ,  A23L1/30 ,  A23L1/302 ,  A61K31/353 ,  A61K31/592 ,  A61K31/593 ,  A61K31/7048 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/14 ,  A61P7/08 ,  A61P13/12 ,  A61P19/00 ,  A61P19/10 ,  A61P25/00 ,  A61P35/04 ,  A61P43/00

CPC分类号： A61K31/353 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/592 ,  A61K31/593 ,  A23V2250/2116 ,  A23V2250/714 ,  A23V2250/71 ,  A23V2250/1642

摘要： The present invention is concerned with a method of controlling the plasma genistein concentration in mammals in order to avoid activation of the peroxisome proliferator-activated receptor γ (PPARγ), said method comprising the steps of: a. assessing the genistein blood serum concentration of the mammal; b. if needed, administering to said mammal a genistein component in an amount sufficient to maintain the genistein blood serum concentration at a level between 0.02 and 3 μM during at least 8 hours, preferably at least 16 hours of each day; c. repeating steps a. and b. during a period of at least 30 days with intervals of no more than 3 days. The present method is particularly suited for preventing obesity and diseases or conditions in which bone tissue is lost.

摘要翻译： 本发明涉及一种控制哺乳动物血浆染料木黄酮浓度的方法，以避免过氧化物酶体增殖物激活受体γ（PPARγ）的激活，所述方法包括以下步骤：a。 评估哺乳动物的染料木黄酮血清浓度; b。 如果需要，向所述哺乳动物施用足以将染料木黄酮血清浓度维持在0.02至3μM之间的水平的量的染料木素组分，每天至少8小时，优选至少16小时; C。 重复步骤a。 和b。 至少30天，间隔不超过3天。 本发明的方法特别适合于预防肥胖和其中骨组织丢失的疾病或病症。

公开(公告)号：US06780078B2

公开(公告)日：2004-08-24

申请号：US10285701

申请日：2002-11-01

申请人： Robert Hageman ,  Robert W. Jourdian

发明人： Robert Hageman ,  Robert W. Jourdian

IPC分类号： A63H3000

CPC分类号： A63H19/24 ,  A63H19/10 ,  A63H19/14 ,  A63H19/36 ,  A63H30/04 ,  A63H2019/246

摘要： A toy assembly that includes a remotely controlled vehicle is disclosed. In one embodiment, the toy assembly includes a remote control that can be used to control a toy vehicle. In one embodiment, the remote control includes a chip with pre-recorded content stored thereon. In one embodiment, the remote control can be coupled to an audio amplifier that can generate audible outputs. In another embodiment, the remote control can be used in a hand-held configuration.

摘要翻译： 公开了一种包括遥控车辆的玩具组件。 在一个实施例中，玩具组件包括可用于控制玩具车辆的遥控器。 在一个实施例中，遥控器包括其上存储有预先记录的内容的芯片。 在一个实施例中，遥控器可以耦合到可产生可听输出的音频放大器。 在另一个实施例中，遥控器可以用在手持配置中。

公开(公告)号：US20070232568A1

公开(公告)日：2007-10-04

申请号：US10572240

申请日：2004-09-20

申请人： Klaske van Norren ,  Eduard van Hoorn ,  Robert Hageman ,  Kelly Lamb

发明人： Klaske van Norren ,  Eduard van Hoorn ,  Robert Hageman ,  Kelly Lamb

IPC分类号： A61K31/70 ,  A23L1/30 ,  A61K31/7004 ,  A61K31/715 ,  A61P11/00 ,  A61K31/7016 ,  A23L1/305

CPC分类号： A61K31/715 ,  A23L33/10 ,  A23L33/115 ,  A23V2002/00 ,  A61K31/70 ,  A61K31/7004 ,  A61K31/7016 ,  A61K38/06 ,  A61K2300/00 ,  A23V2250/54246 ,  A23V2250/61 ,  A23V2250/5114 ,  A23V2250/54252 ,  A23V2250/026 ,  A23V2250/606 ,  A23V2250/0634 ,  A23V2250/032 ,  A23V2250/616

摘要： One aspect of the present invention is concerned with a method of treating or preventing pulmonary inflammation as a complication ensuing from physical trauma, bacteraemia or viral inflection, said method comprising enterally administering at least one or more glutathione promoters selected from: −0.3-20 g, preferably 0.5-5 g pyruvate equivalents; −0.1-5 g, preferably 0.2-2 g oxaloacetate equivalents; −0.01-1 g, preferably 0.02-0.5 g lipoic acid equivalents; and at least 20 g of digestible water soluble carbohydrates, in the form of an aqueous liquid composition containing at least 10 g/l of said digestible water soluble carbohydrates. Another aspect of the invention relates to an aqueous liquid composition suitable for enteral administration containing: 2 to 20 wt. % digestible dissolved carbohydrates; two or more glutathione promoters selected from: 0.5 to 50 g/l pyruvate equivalents; 0.05 to 20 g/l oxaloacetate equivalents; 0.05 to 5 g/l cystein equivalents; and at least 45 wt % water.

摘要翻译： 本发明的一个方面涉及一种治疗或预​​防肺部炎症的方法，作为从身体创伤，细菌血症或病毒变形引起的并发症，所述方法包括肠内施用至少一种或多种谷胱甘肽启动子，所述谷胱甘肽启动子选自：-0.3-20g ，优选0.5-5克丙酮酸当量; -0.1-5g，优选0.2-2g草酰乙酸当量; -0.01-1g，优选0.02-0.5g硫辛酸当量; 和含有至少10g / l所述可消化水溶性碳水化合物的含水液体组合物形式的至少20g可消化水溶性碳水化合物。 本发明的另一方面涉及适用于肠内给药的含水液体组合物，其含有：2-20wt。 消化溶解碳水化合物％ 两种或更多种谷胱甘肽启动子，其选自：0.5至50g / l丙酮酸当量; 0.05〜20g / l草酰乙酸当量; 0.05至5g / l半胱氨酸当量; 和至少45重量％的水。